Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : ANNOUNCEMENT ON THE APPROVAL FROM CSRC FOR THE PROPOSED NON-PUBLIC ISSUANCE(H SHARES)

08/02/2021 | 06:22am EDT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥(集 團)股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

ANNOUNCEMENT ON THE APPROVAL FROM CSRC FOR

THE PROPOSED NON-PUBLIC ISSUANCE

References are made to the announcements of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") dated 25 November 2020, 6 April 2021 and 12 July 2021, the overseas regulatory announcements of the Company dated 25 November 2020, 15 January 2021, 22 February 2021, 6 April 2021, 1 June 2021, 5 July 2021 and 12 July 2021, and the circular of the Company dated 8 December 2020 (the "Circular"), in relation to the Proposed Non-public Issuance. Unless otherwise specified, capitalised terms used in this announcement shall have the same meaning as defined in the Circular.

The Board is pleased to announce that the Company received the "Approval in relation to the Non-public Issuance of Shares by Shanghai Fosun Pharmaceutical (Group) Co., Ltd." (Zheng Jian Xu Ke [2021] No.

2501) issued by the CSRC on 30 July 2021. Details of the approval are as follows:

  1. The Company is approved to undertake the non-public issuance of not more than 128,144,927 new Shares (A Shares), subject to adjustment in the event of change in the total share capital as a results of, among others, capital increase.
  2. The issuance of shares shall be implemented strictly in accordance with the application documents submitted by the Company to the CSRC.
  3. The CSRC approval shall be valid for a period of 12 months commencing from the date of the approval (27 July 2021).
  4. The Company shall report, in a timely manner, to the CSRC in the event of occurrence of any material events during the period from the date of the approval for issuance and prior to the completion of the issuance of shares, and shall deal with such events in accordance with the relevant regulations.

1

The Board will deal with the matters pertaining the Proposed Non-public Issuance in accordance with the relevant requirements under the above approval from the CSRC and the relevant authorisation approved by the Shareholders at the general meeting of the Company, and will perform its information disclosure obligations in a timely manner.

Shareholders and potential investors shall exercise caution when dealing in the shares of the Company.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

2 August 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non- executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

  • for identification purposes only

2

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 02 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 August 2021 10:21:02 UTC.


ę Publicnow 2021
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
09/22SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Raises Nearly $186 Million from Sale of Renmi..
MT
09/21SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Wins US FDA Nod to Start Clinical Trial of Ex..
MT
09/21SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement - on completion of the issuance of ..
PU
09/10SHANGHAI FOSUN PHARMACEUTICAL : Proposed adoption of rsu scheme by a subsidiary (h ..
PU
09/02SHANGHAI FOSUN PHARMACEUTICAL : Monthly return of equity issuer on movements in securities..
PU
09/01Helped by TSMC and Foxconn, BioNTech vaccines finally reach Taiwan
RE
09/01SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Secures Another $100 Million For COVID-19 Vac..
MT
08/25REFILE-Taiwan says BioNTech shots available earlier than expected
RE
08/25REFILE-Taiwan to get BioNTech shots early as China delays approval-source
RE
08/24SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Announces 2021 Interim Results Innovative Pro..
PU
More news
Analyst Recommendations on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
More recommendations
Financials
Sales 2021 37 550 M 5 807 M 5 807 M
Net income 2021 4 674 M 723 M 723 M
Net Debt 2021 17 898 M 2 768 M 2 768 M
P/E ratio 2021 31,0x
Yield 2021 0,89%
Capitalization 135 B 20 876 M 20 875 M
EV / Sales 2021 4,07x
EV / Sales 2022 3,47x
Nbr of Employees 34 375
Free-Float 57,5%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 57,32 CNY
Average target price 68,40 CNY
Spread / Average Target 19,3%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman